Einstein Medical Center Philadelphia recently purchased the first clinical LumaGem, a molecular breast imaging (MBI) solution, from Gamma Medica. The move will bring this new secondary screening method that enables early cancer detection in women to Pennsylvania.
Approximately 50% of women in the United States are reported to have dense breast tissue. Many women aren’t aware of this reality—and even if they are, they may not fully comprehend what it means for their increased risk of breast cancer. By way of contrast with mammography, MBI highlights tumors’ metabolic activity—regardless of breast density—and that leads to earlier diagnoses.
Commenting, Philip Croxford, Gamma Medica president and CEO, says: “We are thrilled to partner with the Marion-Louise Saltzman Women’s Center at Einstein Medical Center Philadelphia to increase access to state-of-the art MBI technology for women in Pennsylvania. Partnering with such a prestigious facility and installing a LumaGem MBI system provides the opportunity to help women at risk in the Philadelphia area.”
Debra Somers Copit, MD, director of breast imaging for Einstein Healthcare Network adds, “Einstein Medical Center Philadelphia is thrilled to add Gamma Medica’s LumaGem to our suite of leading breast imaging technology. As a supplement to 3D mammography, MBI will help us detect cancers in dense tissue that may have been missed by mammography alone. We feel confident that LumaGem will support our mission to provide the best diagnostic care for our patients—the data behind MBI speaks for itself.”
For more information about this product, visit Gamma Medica.
